Vascular Biogenics Ltd (VBLT)

[gr8db8]

This was Dror Harats response in the earnings call regarding ovarian patients:

=====

But more than this, we are going to show the type of patients that we are having in this trial and I urge you all to look very carefully at the characteristic of the patients, because in most trial doctors avoid taking patient what we called a primary platinum-refractory patients which are patient who never respond to platinum or that less than three months after responding to platinum already had a recurrent.

I don't want to say the number, but you will see it when we'll have the data at ASCO. I don't think that we put it at the abstract, but you will see it at ASCO itself and it’s a very high number. And the other point is that we are going to show that we have a very high number of patients that's already failed Avastin. So, to have 60% response rate in this type of population is actually a great indication that there is real response that we are seeing here.

=====

In the KOL event he compared VB-111 to Celldex, and also talked about how Celldex's phase 2 and 3 patient populations were different (as a possible reason for the drug's failure).